BioWorld

May 13, 2005

Cephalon's Parkinson's Study Stopped; No Benefit Showed

Cephalon Inc. called a halt to a late-stage study of a partnered Parkinson's disease drug, CEP-1347, as interim results revealed a lack of clinical benefit. (BioWorld Today) Read More

CuraGen Partner Signs CRADA; Subsidiary 454 Enters $62M Deal

Tranzyme's Story: Early Stage Firm Brings In $32M Financing

Spherics Gets $26M To Push Bioadhesive Drug Delivery

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...